Archive | Medical Research

Cystic Fibrosis research plan for Crumlin hospital

Cystic Fibrosis research plan for Crumlin hospital

THE RCSI (Royal College of Surgeons in Ireland) and the National Children’s Research Centre (NCRC) have announced a new partnership that is aimed at strengthening paediatric Cystic Fibrosis (CF) research at Our Lady’s Children’s Hospital, Crumlin.

The €1.1 million research programme that will run for five years will focus entirely on children with CF. It is aimed at strengthening paediatric CF research at Our Lady’s Children’s Hospital to enable research findings to be translated into medical practice. It will be the first dedicated national paediatric CF research programme in Ireland.

It will enable new avenues of research into early CF lung disease in children to be developed, and a plan for a substantial translational research and innovation centre at the new children’s hospital to be established. It will also strengthen links between the NCRC, which is funded entirely through donations to the CMRF, and specialist paediatric CF centres across Ireland.

Professor Ray Stallings, RCSI Director of Research, said they were delighted to join forces and collaborate with NCRC to develop Ireland’s first national paediatric CF research programme in Ireland. “As an exclusively health sciences focused institution, the RCSI is uniquely placed to develop and enhance translational research for the benefit of patients,” he said. “Translational research links basic science research with relevant clinical questions and the aim of this research partnership is to keep young CF lungs healthy.”

The focus of the research is to develop biomarkers of lung disease in Cystic Fibrosis that will help to detect early lung disease in young children. Early detection and treatment will reduce disease progression and improve quality of life. This new initiative links the clinical team at Our Lady’s Children’s Hospital, Crumlin led by Prof Paul McNally, and the basic science team led by Dr Judith Coppinger.

Dr Jacinta Kelly, NCRC Chief Executive, added: “This is a very exciting research partnership which will put Irish research at the forefront of paediatric CF research.

“Ireland has one of the highest incidences of Cystic Fibrosis in the world and as a direct consequence of this it has become a hub for international researchers hoping to find a cure.

“The development of a national paediatric CF programme will bring together research, clinical trials and clinical care for the benefit of patients.”

There are more than 600 children and 700 adults in Ireland with CF and one in 19 Irish people carry a CF gene mutation, making it the most common hereditary condition in children in the country. CF is a progressive disease that can have a huge burden of treatment on children and their families and usually increases over time. Although survival rates have improved, it is still a debilitating condition and can result in early death from respiratory failure.

Posted in Medical Research0 Comments

Irish firm wins award for solution that kills superbugs

Irish firm wins award for solution that kills superbugs

Fatal superbugs that have contributed to the deaths of patients and to outbreaks in Irish hospitals face a new enemy in the form of an award-winning antimicrobial solution.

DIT Grangegorman start-up company Kastus has won a Knowledge Transfer Ireland award, which recognises the achievements of higher-education institutes and publicly funded research organisations in Ireland. The company won the award for its solution, which chief executive John Browne says will kill MRSA, Ecoli, fungus associated with athlete’s foot, and CRE (carbapenem-resistant enterobacteriaceae).

According to Browne, it will kill the “dirty dozen” superbugs listed last month by the World Health Organisation (WHO) including three families of bacteria the WHO describes as of critical importance: acinetobacter, pseudomonas and various enterobacteriaceae, which includes CRE. These can cause bloodstream infections and pneumonia and pose a major risk in hospitals and nursing homes. The WHO list also includes high- and medium-priority drug-resistant bacteria that cause diseases such as gonorrhoea and food poisoning caused by salmonella.

The solution can be used to protect surfaces like smartphones, door handles, toilets, sinks, ceramic floor and wall tiles, glass, metals, ATMs, TVs, handrails, lifts, fridges, microwaves, as well as plastics and paint. The company is currently in negotiations with ceramics companies manufacturing sanitary ceramics.

“Our technology is factory applied,” said Mr Browne. The coating is sprayed into the product and then baked into it in the manufacturing process, forming a super hard surface which is permanent and transparent. The product – sink, urinal, ATM – is then permanently free from superbugs, he said.

In December last year, Kastus received a €1.5 million investment from the Atlantic Bridge University Fund. The company is also supported by Singapore-based investor syndicate Carragh Holdings and by Enterprise Ireland. The firm was involved in a recent Enterprise Ireland trade trip to the Middle East. Kastus is currently taking on more staff.

Posted in Healthcare, Medical Research0 Comments

Amryt to begin Phase 3 trial of drug to treat rare disorder

Amryt to begin Phase 3 trial of drug to treat rare disorder

Amryt Pharma has announced the commencement of “EASE”, the Phase 3 clinical trial of AP101 which offers a potential treatment for Epidermolysis Bullosa (“EB”). Currently there is no known cure for EB, a rare genetic skin disorder which causes the skin to blister and tear at the slightest touch. There are approximately 500,000 people living with EB worldwide and the global market for a treatment in EB is estimated to be in excess of €1.3 billion.

Amryt expects to conduct EASE in approximately 15 countries at over 30 sites and to enrol a total of 164 evaluable patients. Patients will be randomised in a double-blind fashion to AP101 or placebo, and the proportion of patients with completely healed target wounds within 45 days will be evaluated as the primary efficacy endpoint.

Mark Sumeray, Chief Medical Officer of Amryt, said: “We are delighted to have initiated the first site participating in our Phase 3 clinical for AP101, which offers a potential treatment for the rare, genetic skin condition, Epidermolysis Bullosa or EB.”

He added that the study is of “substantial size for such a rare disease and offers the opportunity to evaluate a new topical treatment with the potential to accelerate wound healing in this devastating disorder.”

Posted in Healthcare, Medical Research0 Comments

Trinity’s new Immunology Research Centre seeks funding from SFI

Trinity’s new Immunology Research Centre seeks funding from SFI

Trinity’s newest research centre will find out in early May whether they will receive funding from Science Foundation Ireland (SFI) after a round of interviews and applications that will determine the future of the ambitious immunology institution.

Trinity is currently seeking funding from the Science Foundation Ireland (SFI) to establish the INNATE Inflammation and Immunology Research Centre in the Trinity Biomedical Sciences Institute (TBSI).

In an email to The University Times, Prof Andrew Bowie, the Head of Immunology in Trinity, confirmed that the centre has a “final interview” on March 1st, and should receive SFI’s final decision in early May.

Bowie declined to comment further, due to the sensitive information involved in the application, which is still being considered by SFI. SFI funding would not only see the creation of the centre but also the refurbishment of a space in TBSI in which it will be housed.

The new centre will follow a similar model to that of other Trinity research institutes, collaborating with industry and integrating researchers from other Irish universities, including University College Dublin (UCD) and Maynooth University. The centre will specialise in research on the immune system and inflammation, a bodily reaction at the centre of many diseases, including arthritis, diabetes, cancer and bowel disease.

One of the key members of the new centre is expert in immunology Prof Luke O’Neill. O’Neill was recently granted a lab by GlaxoSmithKline (GSK) in Stevenage, England where he will act as Trinity supervisor to two Trinity PhD students, whom GSK will fund to work with their scientists, researching immunology and inflammatory diseases. Elected as a Fellow in 2016 to the prestigious Royal Society, O’Neill is one of Trinity’s most successful researchers, and has attracted millions in researching funding over the years.

At a meeting of Trinity’s Finance Committee in December, the committee noted that the INNATE proposal has the potential to generate a number of “financial and strategic benefits” for Trinity. The establishment of the centre will also include refurbishment costs for a space in TBSI, with the committee noting that the costs for the space should come from Trinity’s funding contribution to the centre. Rental costs for any additional space will be met, however, by INNATE.

Posted in Innovation, Medical Research, University Investment0 Comments

GMI Launch Genomic Research on Rare Disorders

GMI Launch Genomic Research on Rare Disorders

Irish life-sciences company, Genomics Medicine Ireland Ltd. (GMI) announced on Tuesday that it has partnered with Temple Street Children’s University Hospital and the UCD Academic Centre on Rare Diseases (ACoRD) to launch a groundbreaking research study which will examine children with rare undiagnosed genetic disorders attending Temple Street, and their parents in order to identify the key genetic components of rare disorders. The study will combine advanced scientific technology in genomics, the study of all of a person’s genes, together with detailed clinical information to identify the genetic cause of rare disorders affecting/amongst families in Ireland.

Director of UCD ACoRD Sean Ennis said: “This study will give us a greater understanding of the role of genetics in rare disorders for faster and more accurate diagnoses for patients and to help in the development of more targeted therapies for treating these conditions. Ultimately, in the longer term, we are looking to gain insights that will lead to the prevention of these conditions.”

Rare Disorders affect an estimated 300,000 people in Ireland meaning one person in 12 may have a rare disease at some stage in their lifetime.

Temple Street Children’s University Hospital Research Manager Tara Raftertry said “Genome studies hold significant potential to deliver improvements in the quality of life for future generations of children with rare conditions. The route to diagnosing these disorders often involves multiple tests, some of which can be invasive. We can render these kind of tests unnecessary if we can get better insight to the cause of the rare disorder from the outset.”

Genomics Medicine Ireland hopes to quickly expand the research activity in Rare Disorders beyond the charter study at Temple Street to other research centres in Ireland. It will also be launching additional studies in a number of major chronic and incurable conditions where there is a need to better understand the role genetics and lifestyle play in disease and disease progression.

Posted in Healthcare, Medical Research0 Comments

CÚRAM Awarded €150,000 to Tackle Major Global Health Problems

CÚRAM Awarded €150,000 to Tackle Major Global Health Problems

CÚRAM Investigator Dr. Martin O’Halloran has been awarded a second European Research Council (ERC) grant of €150,000 to support the development of a new medical device for the treatment of hypertension (high blood pressure) that can lead to heart disease and stroke, NUI Galway announced on Tuesday.

The project is a collaboration between Investigators Dr Martin O’Halloran and Dr Conall Dennedy at CÚRAM, the Centre for Research in Medical Devices based at NUI Galway. The Investigators aim to bring the novel medical device towards first-in-man trials within the lifetime of the project.

The widespread presence of hypertension in European countries is currently 28-44%. This amounts to between 200 and 327 million Europeans. Excess production of the hormone aldosterone by the adrenal glands (primary aldosteronism) is the most common endocrine cause and accounts for 8-20% of all hypertension. Current treatment regimens are dissatisfactory and costly, involving either surgery or lifelong drug therapy. Therefore, a cost-effective, minimally invasive and definitive management approach for this underlying cause would present a potential cure for an often undiagnosed and unmanaged disease. This is what is being proposed with the new ERC ‘REALTA’ project.

“The REALTA project plan is very similar to that of a start-up medtech company, where as well as technology development, the team will also examine the competitive landscape, the clinical and regulatory pathway, and reimbursement opportunities”, O’Halloran said. “The overarching goal is to gather sufficient technical, clinical, regulatory and commercial evidence over the course of the next 18 months to be able to spin-out a company that is attractive to external investors. Such investment will be required to take the technology through to Food and Drug Administration (FDA) approval and clinical trials.”

Dr O’Halloran secured his first ERC Starting Grant in 2015 to examine the electrical properties of human tissue, as a platform for novel medical device development in Europe. Supported by a Science Foundation Ireland ERC Support Grant, he established the Translational Medical Device Lab in Galway, the first medical device lab in Ireland to be embedded in a regional hospital, University Hospital Galway, and co-located within the Health Research Board’s Clinical Research Facility. Working closely with Dr Conall Dennedy, Consultant Endocrinologist at NUI Galway, he began to examine the potential of new technologies to treat primary aldosteronism, the most common endocrine cause of hypertension.

Professor Abhay Pandit, Scientific Director of CÚRAM said: “The objectives of CÚRAM are to carry out research on the development of innovative ‘smart’ implantable medical devices, which will benefit patients with chronic ailments such as cardiovascular diseases. I would like to congratulate Dr O’Halloran and Dr Dennedy on their continued research success, which is supported by the excellent multidisciplinary team of clinicians, translational scientists and engineers here at CÚRAM and NUI Galway, which reflects the interests and expertise of investigators in CÚRAM.”

Read the NUI Galway announcement here.

Posted in Healthcare, Medical Research, News, R&D Investment, University Investment0 Comments

Heart Pumping Robotic Sleeve Developed by Galway Researcher

Heart Pumping Robotic Sleeve Developed by Galway Researcher

An innovative soft robotic sleeve that helps hearts to beat has been developed by researchers including Dr. Ellen Roche of National University of Ireland Galway, according to research published on Thursday. The soft robotic sleeve wraps around the organ, twisting and compressing in sync with the beating heart, potentially opening new treatment options for people suffering from heart failure.

Roche is the paper’s first author and former PhD student at the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) and The Wyss Institute of Biologically Inspired Engineering at Harvard University. The research took place at Harvard and at Boston Children’s Hospital.

While other therapeutic systems known as ventricular assist devices (VADs) are already used to sustain end-stage heart failure patients awaiting transplant, they extend lives albeit at a high risk due to the number of complications that can occur resulting from their design. Complications include the risk of clotting requiring patients to take potentially dangerous blood thinner medications. Unlike VADs, the soft robotic sleeve does not directly contact blood, avoiding that risk.

With heart failure affecting 41 million people worldwide, the hope is the device may one day be able to bridge a patient to transplant or to aid in cardiac rehabilitation and recovery. “This research demonstrates that the growing field of soft robotics can be applied to clinical needs and potentially reduce the burden of heart disease and improve the quality of life for patients,” explained Roche, now a postdoctoral researcher with Professor Peter McHugh in biomedical engineering at National University of Ireland Galway, where she also previously studied for her undergraduate degree in Biomedical Engineering.

To create an entirely new device that does not come into contact with blood, the researchers took inspiration from the heart itself. The thin silicone sleeve uses soft pneumatic actuators placed around the heart to mimic the outer muscle layers of the mammalian heart. The actuators twist and compress the sleeve in a similar motion to the beating heart. The device is tethered to an external pump, which uses air to power the soft actuators.

“The sleeve can be customized for each patient”, said Roche. If a patient has more weakness on the left side of the heart, for example, the actuators can be tuned to give more assistance on that side. The pressure of the actuators can also increase or decrease over time, as the patient’s condition evolves.

More research needs to be done before the sleeve can be implanted in humans but the work is an important first step towards an implantable soft robot that can augment organ function.

“This research is really significant at the moment because more and more people are ending up with heart failure,” said Roche. “Soft robotic devices are ideally suited to interact with soft tissue and give assistance that can help with augmentation of function, and potentially even healing and recovery.”

Senior authors on the study are Professor Conor Walsh, director of the Harvard Biodesign Lab, and Dr. Frank Pigula, who was at Boston Childrens Hospital when the research was conducted. The study was co-authored by Markus A. Horvath, Isaac Wamala, Ali Alazmani, Sang-Eun Song, William Whyte, Zurab Machaidze, Christopher J. Payne, James Weaver, Gregory Fishbein, Joseph Kuebler, Nikolay V.Vasilyev and David J. Mooney.

It was supported by the Translational Research Program grant from Boston Children’s Hospital, a Director’s Challenge Cross-Platform grant from the Wyss Institute for Biologically Inspired Engineering, Harvard School of Engineering and Applied Sciences and Science Foundation Ireland.

Posted in Healthcare, Innovation, Medical Research0 Comments

AbbVie and GMI Announce Landmark Population Genomics Alliance

AbbVie and GMI Announce Landmark Population Genomics Alliance

Biopharmaceutical company AbbVie, life-sciences startup Genomics Medicine Ireland Limited (GMI), and WuXi NextCODE, the global contract genomics organisation, launched a long-term strategic alliance on Monday to conduct population genomics research in Ireland aimed at advancing the discovery and development of novel therapeutic approaches to a range of serious diseases. The 15-year collaboration will focus on major chronic diseases within oncology, neuroscience and immunology that affect hundreds of thousands of people in Ireland and hundreds of millions worldwide.

The alliance will result in the sequencing of 45,000 genomes from volunteer participants across Ireland to seek novel insights into the biological processes that underlie complex disease. AbbVie will use the research database developed by GMI to identify new molecular approaches for therapeutic drug discovery and development as well as to develop companion diagnostics. The alliance builds on AbbVie’s substantial existing presence in Ireland, which includes more than 600 employees and investments of more than $130 million since 2013.

“Genomics is transforming the way we understand some of the world’s most devastating diseases and enabling the discovery of new approaches that have the potential to deliver much greater benefit to patients,” said AbbVie Vice President of Pharmaceutical Discovery, Jim Sullivan. “This alliance is an important part of our research strategy and complements our significant footprint here in Ireland.”

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs more than 28,000 people worldwide, almost 600 of which are employed across five sites in Ireland. The company has two manufacturing plants in Sligo and a third in Cork, each of which is uniquely focused on supporting portions of AbbVie’s top 20 products. The company has invested steadily in Ireland since its launch in 2013 announcing capital investments of more than €130m at its three manufacturing centers over the past three years. In late 2015, AbbVie also launched two new therapeutic research collaborations valued at €10 million with academic institutions in Cork and Dublin in partnership with the Science Foundation Ireland (SFI).

Daniel Crowley, acting CEO of GMI, commented: “This partnership validates the vision that created Genomics Medicine Ireland. With AbbVie and WuXi NextCODE we will leverage our deep expertise in life sciences and the unique characteristics of the Irish population to discover critical insights into disease, disease progression, and therapeutic response. The resulting therapies to cure and prevent these diseases will benefit patients both here in Ireland and around the world.”

Founded in 2015, GMI is an Irish life-sciences company leading large-scale, population-based genome research studies on the island of Ireland examining the relationship between genetics, health and disease. It is building a preeminent disease-specific database of population genomics.

“GMI’s alliance with AbbVie demonstrates the potential of GMI to drive world-class innovation in healthcare and provides the opportunity for Irish clinicians and researchers to advance genetic discovery and for patients to benefit from the prospective development of new therapeutics,” said Paul Saunders, Head of Innovation with the Ireland Strategic Investment Fund.

Posted in Healthcare, Medical Research, News, R&D News0 Comments

UCC Awarded Gold Medal for Potential Tropical Disease Vaccine

UCC’s Limited Lactis team was awarded a gold medal recently at the iGEM (international Genetically Engineered Machine) competition in Boston.

More than 600 teams from top universities across the globe, including MIT, Harvard, Stanford, Cambridge and Oxford took part in the competition, which is held up as the gold standard for “research-led education”.

The only Irish entrants in the competition, Limited Lactis used the bacterium Lactococcus lactis, a generally recognised as safe bacterium, commonly used in food production, to develop a potential new vaccine against Leishmaniasis, a neglected tropical disease that is increasing in geographical distribution.

Synthetic Biology is a burgeoning approach to designing and making novel products from biology, which is revolutionising what is possible in tackling world needs in health, energy, food and beyond.

Leishmaniasis affects some of the world’s poorest people and is associated with malnutrition, population displacement, poor housing, a weak immune system and lack of financial resources. An estimated 900,000–1,300,000 new cases and 20,000-30,000 deaths occur annually. Leishmaniasis is linked to environmental changes such as deforestation, building of dams, irrigation schemes, and urbanisation.

The UCC team worked voluntarily, engaging with people in disease-affected regions such as Honduras, where diseases like Leishmaniasis is a serious problem. Team instructor, Yensi Flores, a PhD candidate at the Cork Cancer Research Centre and APC Microbiome Institute, travelled to Honduras to gain an insight into the realities of developing a suitable treatment for Leishmaniasis. She connected the team with various stakeholders on the ground. The team also engaged in significant outreach work, teaching Cork school pupils about synthetic biology and conducting charity fundraising activities.

The team, which was comprised of students from UCC Pharmacy, Medicine, Genetics, and BioMedical Science andhosted by the APC Microbiome Institute, Cork Cancer Research Centre and the School of Biochemistry, received financial support from the APC Microbiome Institute, Breakthrough Cancer Research, UCC College of Medicine & Health, Fyffes, the EU, Janssen and Eli Lilly.

Mark Tangney of Cork Cancer Research Centre & APC Microbiome Institute, sadi: “I was blown away with how much was achieved in such a short time by undergraduate students, and how sophisticated the resulting technology is, all due to the enthusiasm of the students and the power of Synthetic Biology.”

Posted in Food, Healthcare, Innovation, Medical Research, News0 Comments

BD to Build R&D Centre in Limerick

BD to Build R&D Centre in Limerick

Medical Technology company Becton, Dickinson and Company (BD) announced on Friday that it plans to open a research and development centre in Limerick, creating about 100 jobs.

The €21 million investment in the centre includes an extensive renovation of the former UniGolf facility in the National Technology Park. Once completed, it is planned to house more than 200 high-tech positions, including the more than 100 BD jobs that are already in Limerick and 100 new positions.

Minister for Finance Michael Noonan, who attended the announcement, said: “Today’s announcement by BD of 100 jobs makes me very proud of Limerick. The company will now begin the process of giving 100 highly skilled workers the opportunity to improve their own lives through employment and also contribute in a meaningful way to the growth of this world class company. This is the latest in a series of quality jobs announcements in Limerick and is a further endorsement of the people of Limerick, the city itself and the top class educational institutions.”

BD has invested significantly in Ireland since 1964 with two sites in Drogheda and Dun Laoghaire, employing more than 500 people in high-skill positions. With the acquisition of GenCell Biosystems Limited in Limerick, the number of BD employees in Ireland has risen to nearly 600.

The BD Limerick R&D Centre will initially focus on product and software development, clinical research instrumentation and prototype development, primarily for the company’s Life Sciences businesses.

Ellen Strahlman, Executive Vice President R&D and Chief Medical Officer for BD said: “Areas served by activities and products arising from our new R&D Centre of Excellence will include the fields of microbiology and molecular biology, clinical and cellular research analysis, and industrial microbiology. Customers will include hospitals, laboratories and clinics, reference laboratories, industrial laboratories, physicians’ office practices, alternate site health care, academic and government institutions, and research facilities. Limerick will be very important for our strategic growth.”

Posted in Healthcare, Medical Research, R&D Investment0 Comments


Upcoming Events

  • June 29, 2017Inspirefest 2017
AEC v1.0.4

The Magazine